7.29  -0.32 (-4.2%)		04-10 16:00
Open: 7.72 High: 7.94 Volume: 1,761,276		Pre. Close: 7.61 Low: 7.155 Market Cap: 535(M)

Short term
Mid term
Targets	6-month :	9.27	1-year :	10.83
Resists	First :	7.94	Second :	9.27
Pivot price	6.7
Supports	First :	5.73	Second :	4.36
MAs	MA(5) :	7.11	MA(20) :	6.58
	MA(100) :	4.75	MA(250) :	2.57
MACD	MACD :	0.5	Signal :	0.5
%K %D	K(14,3) :	82.8	D(3) :	78.1
RSI	RSI(14): 63.6
52-week	High :	7.94	Low :	0.26

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RLMD ] has closed below upper band by 19.0%. Bollinger Bands are 30.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.95 - 7.99	7.99 - 8.04
Low:	7.06 - 7.1	7.1 - 7.15
Close:	7.22 - 7.3	7.3 - 7.36

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Fri, 10 Apr 2026
[EFFECT] RELMADA THERAPEUTICS, INC. SEC Filing - Stock Titan

Thu, 09 Apr 2026
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale under 424B3 - Stock Titan

Wed, 08 Apr 2026
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider

Mon, 06 Apr 2026
Relmada (NASDAQ: RLMD) raises $100M, adds NDV-01 and sepranolone - Stock Titan

Mon, 06 Apr 2026
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - TradingView — Track All Markets

Mon, 30 Mar 2026
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	105 (M)
Shares Float	90 (M)
Held by Insiders	7.5 (%)
Held by Institutions	51.1 (%)
Shares Short	3,730 (K)
Shares Short P.Month	1,110 (K)

EPS	-1.46
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.17
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-50.3 %
Return on Equity (ttm)	-94.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-46 (M)
Levered Free Cash Flow	-23 (M)

PE Ratio	-5.03
PEG Ratio	0
Price to Book value	6.17
Price to Sales	0
Price to Cash Flow	-16.7

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.